Institution Directory

Clinical trials at Fred Hutchinson Cancer Center

Sites in Seattle, WA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

595

Shown on this page

Local recruiting

329

Top conditions

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Showing 1–12 of 595 matching trials with a site at Fred Hutchinson Cancer Center, Seattle, WA.

Live ClinicalTrials.gov results.

Top conditions

Acute Myeloid Leukemia 28 Breast Cancer 20 Colorectal Cancer 17 Acute Lymphoblastic Leukemia 14 Multiple Myeloma 14 Hematopoietic and Lymphatic System Neoplasm 13

Top therapies

Cyclophosphamide 43 Fludarabine 33 Paclitaxel 25 Pembrolizumab 25 Carboplatin 23 Nivolumab 21

Top lead sponsors

Fred Hutchinson Cancer Center 83 University of Washington 64 National Cancer Institute (NCI) 52 SWOG Cancer Research Network 17 Merck Sharp & Dohme LLC 14 Pfizer 14

Live official records

Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma
Interventions: Atebimetinib, GnP, mGnP; Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 45
States / cities: Huntsville, Alabama • Phoenix, Arizona • Duarte, California + 39 more

Conditions: Lung Carcinoma
Interventions: Educational Intervention, Interview, Questionnaire Administration; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: VEXAS, VEXAS Syndrome
Interventions: Pacritinib, Placebo; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Interventions: Pelabresib, Ruxolitinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 20
States / cities: Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 17 more

Conditions: Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 338
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 261 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Von Hippel-Lindau Disease, Malignant Neoplasms
Interventions: Belzutifan, Nivolumab, Lenvatinib, Cabozantinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 7
States / cities: Boston, Massachusetts • Detroit, Michigan • Philadelphia, Pennsylvania + 3 more

Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 264
States / cities: Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 198 more

Conditions: Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Interventions: ML261; Biological
Lead sponsor: Moonlight Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: St Louis, Missouri • Hackensack, New Jersey • New York, New York + 4 more

Conditions: B-All, Acute Lymphoblastic Leukemia
Interventions: NGS testing; Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Chronic Graft Versus Host Disease
Interventions: Belumosudil, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more

About this Fred Hutchinson Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list Fred Hutchinson Cancer Center in Seattle, WA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Fred Hutchinson Cancer Center

Filter and sort this campus

Top conditions

Top therapies

Top lead sponsors

Live official records

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

About this Fred Hutchinson Cancer Center institution page